These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 454504)

  • 21. No demonstrable relationship between IgM and IgG antinuclear antibody levels and acetylator phenotype in patients with systemic lupus erythematosus.
    Portanova JP; Small CJ; Kohler PF
    Arthritis Rheum; 1985 Sep; 28(9):995-8. PubMed ID: 3899125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Slow acetylation phenotype in systemic lupus erythematosus.
    Fishbein E; Alarcón-Segovia D
    Arthritis Rheum; 1979 Jan; 22(1):95-7. PubMed ID: 758923
    [No Abstract]   [Full Text] [Related]  

  • 23. Acetylator phenotype in spontaneous SLE and rheumatoid arthritis.
    Lawson DH; Henry DA; Lowe J; Reavey P; Rennie JA; Solomon A
    Ann Rheum Dis; 1979 Apr; 38(2):171-3. PubMed ID: 443884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survey of the human acetylator polymorphism in spontaneous disorders.
    Evans DA
    J Med Genet; 1984 Aug; 21(4):243-53. PubMed ID: 6387123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acetylator phenotype and lupus erythematosus.
    Uetrecht JP; Woosley RL
    Clin Pharmacokinet; 1981; 6(2):118-34. PubMed ID: 7011656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of long-term treatment with procaine amide. A prospective study with special regard to ANF and SLE in fast and slow acetylators.
    Henningsen NC; Cederberg A; Hanson A; Johansson BW
    Acta Med Scand; 1975 Dec; 198(6):475-82. PubMed ID: 55060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-acetylation phenotyping with dapsone in a mainland Chinese population.
    Horai Y; Zhou HH; Zhang LM; Ishizaki T
    Br J Clin Pharmacol; 1988 Jan; 25(1):81-7. PubMed ID: 3370194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.
    Woosley RL; Drayer DE; Reidenberg MM; Nies AS; Carr K; Oates JA
    N Engl J Med; 1978 May; 298(21):1157-9. PubMed ID: 306574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The acetylator phenotype of patients with systemic lupus erythematosus.
    Reidenberg MM; Martin JH
    Drug Metab Dispos; 1974; 2(1):71-3. PubMed ID: 4150137
    [No Abstract]   [Full Text] [Related]  

  • 31. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus.
    von Schmiedeberg S; Fritsche E; Rönnau AC; Specker C; Golka K; Richter-Hintz D; Schuppe HC; Lehmann P; Ruzicka T; Esser C; Abel J; Gleichmann E
    Adv Exp Med Biol; 1999; 455():147-52. PubMed ID: 10599336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype.
    Russell GI; Bing RF; Jones JA; Thurston H; Swales JD
    Q J Med; 1987 Oct; 65(246):845-52. PubMed ID: 3329739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.
    Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus.
    Reidenberg MM; Drayer DE
    Angiology; 1986 Dec; 37(12 Pt 2):968-71. PubMed ID: 2433971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aromatic amines and the pathogenesis of lupus erythematosus.
    Reidenberg MM
    Am J Med; 1983 Dec; 75(6):1037-42. PubMed ID: 6196968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism].
    Furet Y; Bechtel Y; Le Guellec C; Bechtel PR; Autret-Leca E; Paintaud G
    Therapie; 2002; 57(5):427-31. PubMed ID: 12611196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.
    Horai Y; Fujita K; Ishizaki T
    Eur J Clin Pharmacol; 1989; 37(6):581-7. PubMed ID: 2612554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ethnic differences in reactions to drugs and xenobiotics. Acetylation.
    Evans DA
    Prog Clin Biol Res; 1986; 214():209-42. PubMed ID: 3523508
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of age, sex and body weight on the dapsone acetylation phenotype.
    Philip PA; Gayed SL; Rogers HJ; Crome P
    Br J Clin Pharmacol; 1987 Jun; 23(6):709-13. PubMed ID: 3606931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acetylation phenotype in patients with systemic lupus erythematosus].
    Iakushkevich TN; Tareeva IE; Tuganbekova SK; Kovaleva VL; Evstaf'eva OL
    Ter Arkh; 1985; 57(8):82-4. PubMed ID: 3865448
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.